Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;5(3):175-86.
doi: 10.2217/cns-2016-0009. Epub 2016 May 26.

Immunotherapy in glioblastoma: emerging options in precision medicine

Tiffany R Hodges  1 , Sherise D Ferguson  1 , Amy B Heimberger  1
Affiliations
Review

Immunotherapy in glioblastoma: emerging options in precision medicine

Tiffany R Hodges et al. CNS Oncol. 2016 Jul.

Abstract

Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

Keywords: glioblastoma; immunotherapy; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The Dr Marnie Rose Foundation, the Ben and Catherine Ivy Foundation, The University of Texas MD Anderson Cancer Center GBM Moonshot Program, and the NIH grants CA1208113, P50 CA127001 and P30 CA016672. AB Heimberger has received research grants from Merck, has been a paid consultant for Bristol Myers Squibb, and receives licensing and royalty fees from Celldex Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Precision immunotherapy schema for newly diagnosed glioblastoma patients.
See this image and copyright information in PMC

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. - PubMed
    1. Kensler TW, Spira A, Garber JE, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev. Res. (Phila) 2016;9:2–10. - PMC - PubMed
    1. Arnedos M, Vicier C, Loi S, et al. Precision medicine for metastatic breast cancer-limitations and solutions. Nat. Rev. Clin. Oncol. 2015;12:693–704. - PubMed
    1. Popper HH, Ryska A, Timar J, Olszewski W. Molecular testing in lung cancer in the era of precision medicine. Transl. Lung Cancer Res. 2014;3:291–300. - PMC - PubMed
    1. Chantrill LA, Nagrial AM, Watson C, et al. Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin. Cancer Res. 2015;21:2029–2037. - PubMed

Publication types